» Authors » Ana Maria Passos-Castilho

Ana Maria Passos-Castilho

Explore the profile of Ana Maria Passos-Castilho including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 19
Citations 115
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Passos-Castilho A, Murphy D, Blouin K, Benedetti A, Panagiotoglou D, Bruneau J, et al.
Viruses . 2024 Mar; 16(3). PMID: 38543755
To achieve hepatitis C virus (HCV) elimination, high uptake along the care cascade steps for all will be necessary. We mapped engagement with the care cascade overall and among priority...
2.
Forouzannia F, Hamadeh A, Passos-Castilho A, Erman A, Yu A, Feng Z, et al.
Liver Int . 2024 Mar; 44(6):1383-1395. PMID: 38445848
Background: Patients with chronic hepatitis C (CHC) can be cured with the new highly effective interferon-free combination treatments (DAA) that were approved in 2014. However, CHC is a largely silent...
3.
Atif J, Udhesister S, Abdelnabi M, Dsouza S, Hung J, Edgar R, et al.
Can Liver J . 2023 Dec; 5(4):441-444. PMID: 38144406
No abstract available.
4.
Dagher O, Passos-Castilho A, Sareen V, Labbe A, Barkati S, Luong M, et al.
J Immigr Minor Health . 2023 Oct; 26(1):3-14. PMID: 37902902
Language barriers (LB) contribute to coronavirus disease 2019 (COVID-19) health inequities. People with LB were more likely to be SARS-CoV-2 positive despite lower testing and had higher rates of hospitalization....
5.
Passos-Castilho A, Murphy D, Blouin K, Benedetti A, Panagiotoglou D, Bruneau J, et al.
J Viral Hepat . 2023 Apr; 30(8):656-666. PMID: 37070269
Immigrants living in low hepatitis C (HCV) prevalence countries bear a disproportionate HCV burden, but there are limited HCV population-based studies focussed on this population. We estimated rates and trends...
6.
Passos-Castilho A, Udhesister S, Fontaine G, Jeong D, Dickie M, Lund C, et al.
Can Liver J . 2023 Mar; 6(1):56-69. PMID: 36908576
Hepatitis C virus (HCV) affects approximately 204,000 Canadians. Safe and effective direct-acting antiviral therapies have contributed to decreased rates of chronic HCV infection and increased treatment uptake in Canada, but...
7.
Darwish I, Harrison L, Passos-Castilho A, Labbe A, Barkati S, Luong M, et al.
PLoS One . 2022 Aug; 17(8):e0272953. PMID: 36001588
Background: Health care workers (HCW), particularly immigrants and ethnic minorities are at increased risk for SARS-CoV-2 infection. Outcomes during a COVID-19 associated hospitalization are not well described among HCW. We...
8.
Passos-Castilho A, Labbe A, Barkati S, Luong M, Dagher O, Maynard N, et al.
J Travel Med . 2022 Apr; 29(6). PMID: 35417000
Background: Ethnoracial groups in high-income countries have a 2-fold higher risk of SARS-CoV-2 infection, associated hospitalizations, and mortality than Whites. Migrants are an ethnoracial subset that may have worse COVID-19...
9.
Greenaway C, Greenwald Z, Akaberi A, Song S, Passos-Castilho A, Abou Chakra C, et al.
Lancet Infect Dis . 2020 Jul; 21(1):116-126. PMID: 32711690
Background: Many immigrants are susceptible to varicella on arrival to Canada because of different transmission dynamics in their countries of origin and scarcity of vaccination. Universal childhood vaccination programmes decrease...
10.
Passos-Castilho A, Marchand C, Archambault D
Virology . 2018 Jan; 515:158-164. PMID: 29289827
The bovine immunodeficiency virus (BIV) Rev shuttling protein contains nuclear/nucleolar localization signals and nuclear import/export mechanisms that are novel among lentivirus Rev proteins. Several viral proteins localize to the nucleolus,...